Boston Scientific invests $1.5 billion in MiRus with option to buy heart-valve business

Boston Scientific said it has invested $1.5 billion in MiRus LLC, taking about a 34% equity stake and gaining an exclusive option to acquire the company’s transcatheter aortic valve replacement business.

The deal gives Boston Scientific a potential path back into the balloon-expandable TAVR market through MiRus’s investigational SIEGEL valve system. The company said the valve is not yet approved for commercial distribution.

According to Boston Scientific’s announcement, the option is tied to clinical and regulatory milestones and could involve additional payments of up to $3.0 billion. The company said the investment is expected to be immaterial to adjusted earnings per share in 2026.

What the deal means

Boston Scientific has been expanding its structural heart business, and the MiRus transaction gives it a staged way to re-enter a segment that remains clinically important and commercially large.

MiRus is developing the TAVR system, but the asset remains investigational, so the transaction is still centered on future execution rather than an immediate product launch.

The company disclosed the transaction in a press release and an 8-K filing on May 18, with Reuters later reporting the same terms. The immediate focus now is on MiRus’s ongoing clinical and regulatory path.

What comes next

Boston Scientific’s option to buy the heart-valve business is not automatic. Whether it ultimately moves ahead will depend on the milestones set out in the agreement and the progress of MiRus’s program.